Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF

<table>Proposed mechanism of the tumor homing properties of NGR-TNF. Ultra low dose NGR-TNF can interact more efficiently with CD13-positive tumor vessel, compared to CD13-negative normal vessels, by virtue of high avidity interactions of the CNGRC domain with CD13 and of the TNF domain with TNF receptors (TNF-Rs), thereby triggering local activation of endothelial cells, and inducing leukocyte adhesion molecules, cytokine secretion, procoagulant activity, and apoptosis.</table>

Journal of Oncology

fig3

Figure 3

Figure 3: Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF 

Figure 3 | Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF 